Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China

This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
The primary objective is to compare the risk of the composite outcome of cardiovascular (CV) death or hospitalisation for heart failure (HHF) in heart failure with reduced ejection fraction (HFrEF) patients initiating Jardiance with propensity score (PS) matched HFrEF patients initiating guideline-recommended non-sodium-glucose cotransporter-2 inhibitors (SGLT2i) medications (angiotensin-converting-enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), betablockers, and mineralocorticoid receptor antagonist (MRA)) in China, measured by the hazard ratio of the two groups.

Start Date31 Jan 2028

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT03867487

/ Not yet recruitingPhase 2IIT

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

Start Date01 May 2027

Sponsor / Collaborator

Ann & Robert H. Lurie Children's Hospital of Chicago

NCT07228195

/ Not yet recruitingPhase 4IIT

SGLT2i Therapy in Islet Transplantation (SIT)

This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.

Start Date15 Jul 2026

Sponsor / Collaborator

University of Minnesota

100 Clinical Results associated with Empagliflozin

100 Translational Medicine associated with Empagliflozin

100 Patents (Medical) associated with Empagliflozin

3,905

Literatures (Medical) associated with Empagliflozin

01 Sep 2026·LIFE SCIENCES

Cardioprotective effects of metformin and empagliflozin in STZ-induced diabetic rats: Role of BACH1-mediated ferroptosis and YAP1/PD-L1 signaling

Article

Author: Elsukary, Ahmed E ; Hassan, Yomna F ; Yahia, Ola A ; Elzeiny, Dina ; Abdel-Halim, Nehal H M ; Elsherbini, Sara E ; Elshenawy, Dina S

AIMS:

Diabetic cardiomyopathy (DCM) is a serious complication driven by diabetes-associated oxidative stress and ferroptosis. This study compared the cardioprotective efficacy of metformin and empagliflozin in streptozotocin (STZ)-induced diabetic rats, focusing on ferroptosis-related mechanisms.

MATERIALS AND METHODS:

Forty adult male Sprague-Dawley rats were divided into a control group (n = 10) and a diabetic group induced by STZ (55 mg/kg; n = 30). Following successful induction, the surviving diabetic rats were subdivided into untreated, metformin-treated (200 mg/kg/day), and empagliflozin-treated (10 mg/kg/day) subgroups (n = 8 each). After 12 weeks, biochemical, molecular, and histological analyses were conducted.

KEY FINDINGS:

Diabetic rats showed a 6.4-fold increase in fasting blood glucose (FBG) and a 3.9-fold rise in lactate dehydrogenase (LDH). These systemic changes were accompanied by marked myocardial oxidative stress imbalance and a 1.5-fold increase in cardiac iron. BTB and CNC homology 1 (BACH1) mRNA expression was upregulated 2.2-fold, coupled with suppression of heme oxygenase 1 (HO-1) and glutathione peroxidase 4 (GPX4) to 0.5 and 0.7-fold, respectively. Histological analysis revealed a 4-fold increase in the percentage area of collagen fibers, alongside a 6.2-fold and 4.5-fold increase in Yes-associated protein 1 (YAP1) and programmed death ligand 1 (PD-L1), respectively, and a 0.3-fold reduction in nuclear factor erythroid 2-related factor 2 (NRF2) expression, accompanied by ultrastructural damage characteristic of ferroptosis. Empagliflozin significantly improved antioxidant status, molecular and immunohistochemical marker expression, and myocardial integrity more effectively than metformin.

SIGNIFICANCE:

Empagliflozin demonstrated greater cardioprotective effects than metformin in STZ-induced DCM, though further clinical studies are needed to confirm the translational relevance.

01 Aug 2026·BIOCHEMICAL PHARMACOLOGY

SGLT2i-Triggered hyperglycosuria Unveils CDKN2A-Driven distal tubular senescence and EMT, Fueling renal fibrosis

Article

Author: Bai, Yun-Feng ; Hong, Quan ; Fu, Yi-Fei ; Zhang, Zi-Yue ; Chen, Xiang-Mei ; Zheng, Sheng-Chun ; Deng, Wei-Zhu ; Gong, Na ; Chen, Yan ; Sun, Xue-Feng

SGLT2 inhibitors are widely recommended by clinical guidelines for managing diabetes, cardiovascular, and kidney diseases. High glucose induces proximal tubular epithelial cell senescence and epithelial-mesenchymal transition (EMT), promoting renal interstitial fibrosis. However, the impact of SGLT2 inhibitor-induced hyperglucosuria on distal tubular cell biology remains unreported. C57BL/6 or db/db mice were administered empagliflozin via oral gavage for 4 weeks. Tissues were collected post-intervention to assess the immediate effects on distal tubular cell senescence and EMT. After treatment cessation, C57BL/6 and db/db mice were maintained for another 24 and 11 weeks respectively to investigate subsequent effects. In vitro, mouse distal convoluted tubule (mDCT) cells were stimulated with high glucose to verify mechanisms of glucose-induced senescence and EMT. Empagliflozin induced hyperglucosuria that persisted post-cessation. In C57BL/6 mice, immediate effects led to senescence marked by CDKN1A upregulation and EMT in distal tubular cells. Twenty-four weeks post-cessation, these cells exhibited senescence with co-upregulation of CDKN2A and CDKN1A, EMT progression, and renal interstitial fibrosis. In db/db mice, immediate effects did not exacerbate senescence or EMT, but 11 weeks post-cessation aggravated senescence, EMT progression, and renal interstitial fibrosis. In vitro, high glucose promoted reactive oxygen species (ROS) generation, exacerbated DNA damage, and induced mDCT cell senescence and EMT by upregulating CDKN2A. This study first demonstrates that persistent SGLT2 inhibitor-induced hyperglucosuria drives distal tubular cell senescence, EMT, and renal interstitial fibrosis in wild-type and db/db mice, providing foundational evidence for a more comprehensive understanding of these drugs.

01 Aug 2026·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

SGLT2i combined with physical training attenuates metabolic dysfunction and pyroptosis-mediated renal cell death in diabetic kidney disease

Article

Author: Nagashima, Seigo ; Rocha, Mateus T ; de Noronha, Lucia ; Pinho, Ricardo A ; Lass, André D ; de Moraes, Thyago Proença ; Pedroso, Giulia S ; Marques, Tamyres L ; Mehanna, Samya H ; Zazula, Mateus F ; Machado-Júnior, Paulo Ab ; Silveira, Paulo Cl ; Marques, Larissa C ; Nailiko, Katya

Diabetic kidney disease (DKD) treatment remains a significant clinical challenge; however, despite the recently demonstrated benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the residual risk of progression is still present, and strategies involving combined interventions may provide additional benefits. We investigated the effects of SGLT2i (empagliflozin, 35 mg/kg/day) and moderate-intensity physical training (50-min sessions every 48 h at 60-80% of maximal velocity), both individually and in combination, on DKD progression. Male C57BL/6J mice exposed to a high-fat diet and a single dose of streptozotocin (40 mg/kg) were assigned to four groups (n = 12/group): Control, SGLT2i, physical training (PhTr), and SGLT2i + PhTr. Mice were evaluated over 25 weeks. Body mass, caloric intake, blood glucose, glomerular morphology, neutrophil gelatinase-associated lipocalin (NGAL) expression, oxidative stress markers, inflammatory cytokines, and inflammasome-pyroptosis axis were evaluated. At week 25, the SGLT2i + PhTr group exhibited significantly lower body mass than the Control group. SGLT2i and SGLT2i + PhTr demonstrated the most pronounced effects on blood glucose level reduction. All treatments improved glomerular morphology and reduced NGAL expression. SGLT2i treatment decreased oxidative stress markers in kidney tissue, whereas the combined therapy modulated inflammatory cytokines in skeletal muscle. All interventions reduced gasdermin D immunoexpression despite unchanged inflammasome components. These findings highlight distinct renal- and muscle-specific responses to SGLT2i and PhTr. Both single and combined interventions demonstrated distinct effects in experimental DKD, underscoring the potential benefits of a multimodal therapeutic approach.

349

News (Medical) associated with Empagliflozin

25 Jun 2026

·www.biospace.com

MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b

The appointments position MRM Health for its next key clinical, partnering and financing milestones GHENT, Belgium--(BUSINESS WIRE)-- #biotechnology --MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, today announced the appointment of two experienced industry leaders to its Board of Directors as the Company enters a pivotal phase of growth. With its lead program, MH002, in Phase 2b clinical development, recent FDA Fast Track designation and a €55 million Series B financing, MRM Health is strengthening its Board to support the Company through its next clinical, strategic and financing milestones. Michel Detheux, PhD, has been appointed Chairman of the Board of Directors, taking over from Werner Cautreels. Prof. Dr. med. Hans-Jürgen Wörle joins the Board as an Independent Director. “MRM Health is entering a pivotal phase, with MH002 advancing into Phase 2b clinical development and significant momentum across the business. The appointments of Michel and Hans-Jürgen significantly strengthen our Board with proven leaders in drug development, regulatory strategy, capital markets, strategic transactions and M&A. This Board has been assembled to support MRM Health as we advance MH002 through Phase 2b, prepare for late-stage development and position the Company for its next key milestones. Backed by our CORAL® platform and the positive Phase 2a data generated to date, we are convinced MH002 can become a cornerstone of next-generation microbiome therapeutics,” said Dr. Sam Possemiers, CEO of MRM Health . Proven leaders with expertise spanning biotech company-building, late-stage development and microbiome therapeutics As Chairman, Dr. Detheux brings more than three decades of experience in innovation and value creation in life sciences. He is internationally recognized as a biotech entrepreneur and active board member. As founding Chief Executive Officer of iTeos Therapeutics, he led the company from its inception through a successful crossover financing and NASDAQ IPO, raising a total of $335 million in 2020. He subsequently spearheaded iTeos’ landmark $2 billion strategic collaboration with GlaxoSmithKline for its lead clinical program. Dr. Detheux currently serves as Chairman of the Board at Egle Therapeutics and as a board member at Vor Bio. He holds a degree in bioengineering, a PhD in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School. "MRM Health has established a unique position at the intersection of microbiome science, clinical excellence and industrial scalability. MH002 is a promising candidate with the potential to fundamentally transform the treatment of immune-mediated diseases in the gut. I look forward to working closely with the management team and the Board of Directors to help shape the next stage of the Company's development," said Michel Detheux, PhD. New Independent Director Prof. Dr. med. Hans-Jürgen Wörle is a highly accomplished, board-certified internist with longstanding experience in gastrointestinal diseases, as well as an endocrinologist and diabetologist, with senior R&D executive expertise across the entire drug development continuum. Prof. Wörle previously served as Global Vice President Medicine at Boehringer Ingelheim, where he drove the development and global success of major diabetes therapies, including Jardiance® and Trajenta®, and secured the first-ever FDA cardiovascular-mortality claim for a diabetes medicine. More recently, he was Chief Scientific and Medical Officer at Nestlé Health Science, where he was instrumental in transforming the organization into a science-driven healthcare business, played a critical role in the development and successful commercial transaction of Vowst®, the first FDA-approved oral microbiome therapy, and contributed to several landmark deals and product launches. He brings substantial M&A and investor-side experience across multiple acquisitions, in-licensing transactions and R&D collaborations. He advises biotech boards, CEOs and investors at critical inflection points. He holds an MD from the University of Munich. “The microbiome field has moved from promise to proof, and the question now is which programs can be developed with the rigor and discipline that regulators and patients require. Having helped bring the first approved oral microbiome therapy through development, I see in MRM Health’s differentiated CORAL® platform and promising MH002 clinical data in inflammatory bowel diseases the combination of science and execution that defines the next generation. I believe MH002 has great potential to address a major unmet medical need and am joining the team to help translate this into clinical reality for patients,” said Prof. Dr. med. Hans-Jürgen Wörle . MRM Health would like to thank Werner Cautreels, who has chaired MRM Health since the Company’s founding in 2020, for his invaluable contributions to the Company’s development. Werner played an important role during a period of significant growth, including successful financing rounds and the continued advancement of MH002 toward late-stage clinical development. *** About MRM Health MRM Health is a clinical-stage biotech developing innovative Live Biotherapeutic Products (LBPs) for immune-mediated diseases with high unmet needs. Its CORAL® platform enables the design and manufacture of disease-focused microbial consortia with enhanced efficacy and scalability. The Company’s lead program, MH002, for inflammatory bowel diseases (IBD) has shown positive Phase 2a clinical data in ulcerative colitis and pouchitis and is now advancing into late-stage clinical development. MRM Health is expanding its pipeline across other inflammatory diseases and immune-oncology, leveraging AI-guided discovery and deep expertise in microbiome ecosystem biology. In September 2025, MRM Health successfully closed a €55 million Series B round led by Biocodex, with strong support from ATHOS, BNP Paribas Fortis Private Equity and existing investors SFPIM, AvH, OMX Europe VF, QBIC II and VIB. For more information, please follow us on LinkedIn or visit the website at . Contacts Corporate MRM Health NV Dr. Sam Possemiers – CEO info@mrmhealth.com Media relations International & DACH MC Services AG Anne Hennecke Phone: +49.151.125.557.59 anne.hennecke@mc-services.eu Media relations BeNeLux/France Backstage Communication Gunther De Backer Phone: +32.475.903.909 gunther@backstagecom.be

Phase 2Executive ChangeMicrobial therapyIPOFast Track

12 May 2026

·www.einpresswire.com

RTW Foundation Awards $573,000 to Rare Disease Foundations Advancing Ultra-Rare Disease Research

RTW Foundation is proud to announce $573,000 in grant funding for eight rare disease foundations advancing critical rare disease research. NEW YORK CITY, NY, UNITED STATES, May 12, 2026 / EINPresswire.com / -- RTW Foundation, the philanthropic arm of biotech investment firm RTW Investments, is proud to announce $573,000 in grant funding for eight rare disease foundations advancing critical rare disease research, each led by families and patient-led organizations working at the front lines of research, patient engagement, and therapeutic development. Rare disease foundations play an essential role in accelerating research, mobilizing patient communities, supporting studies, facilitating trial readiness, and bridging the gap between families, researchers, and the pharmaceutical industry. Together, these organizations are addressing urgent unmet needs across the rare disease landscape, where complexities in treatment options, small patient populations, and limited funding often slow progress toward treatment. RTW Foundation’s rare disease grants support essential work across the full research and development pipeline, from early laboratory studies and animal models to safety and toxicology assessments and preparation for clinical trials. Beyond grant funding, RTW Foundation works closely with each organization through its Rare Disease Advisory Program (RDAP), providing free scientific and strategic advising to help rare disease foundations evaluate research priorities, therapeutic opportunities, and key translational next steps. “We’re incredibly grateful to support our rare disease partners, whose leadership, urgency, and lived experience continue to drive meaningful progress,” said Nicole Litt, Program Manager at RDAP. “It’s a privilege to stand alongside families as they push research, expand access, and bring hope to patients around the world.” Birdie's Flight for a KDM5C Cure is a family-led foundation dedicated to advancing treatment for KDM5C-related disorders, including rare X-linked neurodevelopmental conditions caused by KDM5C deficiency. Through RDAP, Birdie’s Flight is supporting n-Lorem Foundation’s work to design and develop ASOs that target regulatory elements within KDM5C transcripts, with the goal of increasing endogenous KDM5C protein levels. This upregulation approach, distinct from gene editing or gene replacement, may inform therapeutic strategies not only for KDM5C-related disorders but also for other conditions where increasing expression of the native gene product may be beneficial. CHAMP1 Research Foundation is dedicated to finding treatments for CHAMP1 syndrome, a rare neurodevelopmental disorder caused by pathogenic variants in the CHAMP1 gene. Through RDAP, CHAMP1 Research Foundation will develop an RNA-based target-site blocker therapeutic approach designed to restore CHAMP1 protein levels in patient-derived neurons and preclinical mouse models. This work aims to establish proof-of-concept for a haploinsufficiency-targeted strategy and lay the groundwork for future translational development. Miracles for Mighty Milo Foundation is a family-led organization advancing research for SPAX5, also known as spastic ataxia type 5, a rare AFG3L2-associated neurologic disorder. Through RDAP, the Foundation is supporting the transfer of Milo-derived iPSC lines to Dr. Francesca Maltecca’s laboratory at IRCCS Ospedale San Raffaele in Milan and funding initial feasibility experiments to evaluate AAV-mediated gene addition in patient-derived neural cells. This work will generate human-relevant data to support follow-on funding and help advance the program toward therapeutic development. The MYT1L Project Foundation is committed to finding treatments for MYT1L neurodevelopmental syndrome, a rare condition caused by haploinsufficiency of the MYT1L gene. Through RDAP, the Foundation is supporting a multi-institution collaboration to screen and identify lead ASO candidates designed to increase productive MYT1L expression, with validation in iPSC-derived neurons and patient-derived cells. The goal is to identify potent, well-characterized lead sequences that can advance into preclinical proof-of-concept studies. Shwachman-Diamond Syndrome Alliance is a patient advocacy organization dedicated to improving outcomes for individuals living with Shwachman-Diamond syndrome, a rare multisystem disorder affecting the bone marrow, pancreas, and other organ systems. Through RDAP, the Foundation is supporting development of a prime editing-based strategy to evaluate whether precise correction of the underlying genetic defect could provide a durable therapeutic path for the SDS community. Sophie's Hope Foundation/CureGSD1b is a patient advocacy organization focused on improving the lives of individuals with Glycogen Storage Disease Type Ib, a rare metabolic disorder affecting glucose regulation and immune function. Through an RDAP grant, the organization will develop a comprehensive natural history study at UTHealth Houston to characterize the clinical course of GSD Ib, including metabolic complications, neutropenia, enterocolitis, liver disease, and response to emerging treatments such as empagliflozin. The data collected will inform genotype-phenotype correlations and support future therapeutic development efforts. The Styrke Foundation is a patient advocacy organization dedicated to accelerating treatment development for Diamond-Blackfan anemia syndrome (DBAS). Through RDAP, RTW Foundation is supporting the organization in producing the first-ever externally led Patient-Focused Drug Development meeting with the FDA for DBAS, conducting a comprehensive patient and caregiver survey, and developing a Voice of the Patient report to inform future therapeutic development. This work also supports the launch of Styrke Canada and the development of a DBAS natural history study. The TESS Research Foundation is dedicated to finding treatments for SLC13A5 epilepsy, a rare and severe developmental and epileptic encephalopathy caused by loss-of-function variants in the citrate transporter gene SLC13A5. Through an RDAP grant, the Foundation is supporting development of novel drug-screening assays to identify small-molecule activators of SLC13A5, a high-priority and underexplored therapeutic strategy given that existing compounds are inhibitors and therefore unsuitable for a loss-of-function disease. Natural history data suggest that even partial restoration of SLC13A5 activity may benefit patients, making this a compelling opportunity for drug discovery. About RTW Foundation Founded in 2018 as the philanthropic arm of RTW Investments, LP, RTW Foundation works to power community initiatives and provide scientific advising to improve the health of underserved populations. The Foundation supports the development of medicines for neglected rare diseases, empowers youth to explore careers in science, biotechnology, and medicine, and builds partnerships with local organizations to advance health equity in New York City. To learn more, visit www.rtwf.org . Samantha Darris RTW Foundation email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

25 Mar 2026

·www.biospace.com

Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025

Boehringer biopharma production Press photo Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments grew to EUR 6.4 billion, equivalent to 22.9% of group net sales 70 million patients reached in 2025, up from 66 million in 2024 Ingelheim, March 25, 2026 – Boehringer Ingelheim successfully delivered on key launches in its Human Pharma business in 2025, bringing two medicines with FDA Breakthrough Therapy designation for lung cancer and pulmonary fibrosis to market in the second half of 2025. Group net sales rose by 7.3%* to EUR 27.8 billion for the full year, supported by both the Human Pharma and Animal Health business. In 2025, Boehringer increased Research and Development (R&D) investments to EUR 6.4 billion, representing 22.9% of group net sales. The company reached 70 million patients in 2025, delivering innovative medicines to more patients than ever before. “2025 reinforced the strength of our pipeline and underscored the impact of our long-term investment in R&D. With two newly launched medicines in oncology and respiratory, we are addressing high unmet medical needs of patients, while also driving the renewal of our portfolio. Our pipeline positions us well to continue to make a real difference across important disease areas, and to bring innovative therapies to more patients than ever,” said Shashank Deshpande, Chairman of the Board of Managing Directors and responsible for Human Pharma. “As 2026 unfolds with pivotal Phase III programs and readouts as well as new launches ahead, we strive to improve the lives of patients, animals, and communities worldwide.” Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: “In volatile markets and amid regional challenges, our business proved resilient as we focused on what we do best: bringing more medicines to patients and animals. We are investing more than ever in innovation, which reflects our ambition for the next years.” Human Pharma: JARDIANC E® (empagliflozin) and OFEV® (nintedanib) continue to grow; HERNEXEOS® and JASCAYD® launched Human Pharma sales rose 7.4%* to EUR 22.7 billion, supported by strong performance in its core brands. JARDIANCE®, for the treatment of chronic kidney disease, type 2 diabetes and heart failure, grew 8.7%* to EUR 8.8 billion. Sales for OFEV®, used to treat idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases, increased 5.4%* to EUR 3.8 billion. Boehringer Ingelheim expanded its portfolio with the launch of two innovative therapies in 2025: HERNEXEOS®, an oral treatment for HER2-mutant advanced non-small cell lung cancer, was launched in the U.S. in August 2025. The company also launched JASCAYD®, which was approved in the U.S. and China for idiopathic pulmonary fibrosis (IPF) in October 2025, and for progressive pulmonary fibrosis (PPF) in December 2025. JASCAYD® represents the first new innovative therapy for IPF coming to market in more than a decade. Human Pharma R&D investments came in at EUR 5.8 billion or 27.4% of the unit’s net sales. The company continued to advance its pipeline across cardiovascular, renal and metabolic diseases (CRM), oncology, respiratory and immunology, mental health, and eye health. The pipeline today includes more than 80 projects, representing over 50 new molecular entities. Ongoing advances in Boehringer’s growing mid‑ and late‑stage pipeline are building towards a sustained wave of potential launches, positioning the company to deliver transformative impact for patients in the years to come. Animal Health: preventing the spread of transboundary animal diseases In 2025, the Animal Health business demonstrated resilience and impact, with sales rising 6.5%* to EUR 4.9 billion. Growth was driven by pet parasiticides and therapeutics, poultry, and ruminant segments, with NEXGARD® growing 8.5%* to EUR 1.4 billion, cementing its position as the industry’s top-selling parasiticide brand. The company worked side by side with farmers, veterinarians, and governments, to help combat livestock diseases such as avian influenza, foot-and-mouth disease, and bluetongue virus. Boehringer received EU Marketing Authorization under Exceptional Circumstances for two poultry vaccines, supporting producers in keeping their poultry flocks healthy and increasing preparedness for avian influenza outbreaks. In addition to the VAXXINACT® H5 avian influenza vaccine, VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine protecting chickens and turkeys against Marek’s disease, Infectious Bursal Disease and H5 avian influenza. Outlook In 2026, Boehringer expects to build on the momentum of recent years with continued progress across the Animal Health and Human Pharma pipelines and critical inflection points particularly in CRM, oncology and eye health. * sales growth numbers are adjusted for currency Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at . Attachment Boehringer biopharma production

Drug ApprovalPhase 3Breakthrough Therapy

100 Deals associated with Empagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D10459	Empagliflozin	A10BK03	DB09038

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	China	Boehringer Ingelheim GmbH	26 May 2023
Cardiovascular Diseases	China	Boehringer Ingelheim International GmbH	26 May 2023
Heart failure with normal ejection fraction	China	Boehringer Ingelheim International GmbH	30 Aug 2022
Heart failure with normal ejection fraction	China	Boehringer Ingelheim (China) Investment Co., Ltd.	30 Aug 2022
Heart failure with reduced ejection fraction	China	Boehringer Ingelheim GmbH	10 Jun 2022
Heart failure with reduced ejection fraction	China	Boehringer Ingelheim International GmbH	10 Jun 2022
Chronic heart failure	European Union	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Iceland	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Liechtenstein	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Norway	Boehringer Ingelheim International GmbH	22 May 2014
Chronic Kidney Diseases	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014
Diabetes Mellitus, Type 2	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014
Heart Failure	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Defects, Congenital	Phase 3	Canada	Boehringer Ingelheim GmbH	01 May 2025
Glycosuria, Renal	Phase 3	Egypt	Tanta University	25 May 2023
Schizophrenia	Phase 3	Egypt	Tanta University	25 May 2023
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Egypt	Tanta University	01 Nov 2022
Hypoglycemia	Phase 3	Switzerland	Boehringer Ingelheim GmbH	11 Mar 2022
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim GmbH	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim Pharma GmbH & Co., KG	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim International GmbH	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Eli Lilly & Co.	16 Dec 2020
Acute myocardial infarction	Phase 3	China	Eli Lilly & Co.	16 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05042973 (Empire Prevent Metabolic, Pubmed \| Cardiovasc Diabetol)	Phase 2	Overweight	92	Empagliflozin 10 mg	pngkxwnptm(afjjrvzdog): ETR = 1.03 (95.0% CI, 0.82 - 1.3), P-Value = 0.78 View more	Negative	12 Jun 2026
				Placebo
NCT03198585 (Empire HF, Pubmed \| ESC Heart Fail)	Phase 2	Heart failure with normal ejection fraction	190	Empagliflozin 10 mg	eprsxaemfv(obdsdvhplu) = No significant treatment effect was observed in the middle or highest tertiles of RVFWS. lswrudqpel (lttljlpaos )	Negative	05 May 2026
NCT03790787 (Pubmed \| Nat Commun)	Phase 1	Diabetes Mellitus, Type 2 \| Obesity	16	Dorzagliatin+Empagliflozin	ljwizjsooq(tamimylofs) = cmbjfxxajm ipovzbdnld (wnonanxmfp ) View more	Positive	21 Apr 2026
NCT04157751 (EMPULSE, Pubmed \| JACC Heart Fail)	Phase 3	Heart Failure	530	Empagliflozin 10 mg/d	kkbiauxqpb(hhgyyuyqno) = The win ratio was 1.29 (95% CI: 0.89-1.89) for NHF and 1.39 (95% CI: 1.07-1.81) for ADHF (P interaction = 0.759). There were no interactions between NHF and ADHF for the primary endpoint, its components, or secondary endpoints, except diuretic response, which was greater with empagliflozin in NHF than in ADHF from day 15 (mean difference vs placebo: -5.11 [Q1-Q3: -7.89 to -2.32] vs -0.97 [Q1-Q3: -2.91 to 0.96] kg per mean daily loop diuretic dose, P interaction = 0.017), with even greater between-group differences at days 30 and 90. zwmsbykyvi (mtqwlimjtj ) View more	Positive	01 Mar 2026
				Placebo
NCT03594110 (EMPA-KIDNEY, Pubmed \| Clin Ther)	Phase 3	Chronic Kidney Diseases	6,609	Empagliflozin 10 mg	juxidfcuep(olgyontbeb) = Mean cumulative incidence of ACH in empagliflozin and placebo groups diverged shortly after randomization and separated further over time. suoxzzkiyy (ceclnktydr ) View more	Positive	01 Dec 2025
				Placebo
NCT06140108 (Pubmed \| BMC Womens Health)	Phase 4	Polycystic Ovary Syndrome	80	Empagliflozin 10 mg	kuktsxkffu(khfltzxkmm) = dhpqszxqcx drgixseujw (zmlirrbgrg, 2.0) View more	Positive	19 Nov 2025
				Metformin 500 mg	kuktsxkffu(khfltzxkmm) = bgirmpbjjo drgixseujw (zmlirrbgrg, 3.2) View more
CONFIDENCE (ASN2025)	Not Applicable	Diabetes Mellitus, Type 2	798	Finerenone	jgvzfwxjtr(ztexhpweih) = bojtdjfjck ttixncoytq (caxnfojvib )	Positive	07 Nov 2025
				Empagliflozin	jgvzfwxjtr(ztexhpweih) = chnlzerfvn ttixncoytq (caxnfojvib )
NCT05254002 (CONFIDENCE, Pubmed \| J Am Coll Cardiol)	Phase 3	Type 2 diabetes mellitus with established diabetic nephropathy \| Chronic Kidney Diseases	779	Empagliflozin + Finerenone	ehsagsbekh(qlebbntxpk) = yumjcoenhc bbbfbdzvkx (fgcetfytiw )	Negative	01 Nov 2025
				Finerenone	ehsagsbekh(qlebbntxpk) = hswahugeal bbbfbdzvkx (fgcetfytiw )
NCT05081219 (CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	47	Aptar Pharma CPS Intranasal Delivery Device+Insulin (Humulin® R U-100) (Intranasal Insulin and Empagliflozin Placebo)	fugaduamog = rkumwudkwh koboukuzky (lmcjkzlrxd, fqtlmbtcnw - twzmljsklc) View more	-	21 Oct 2025
				Aptar Pharma CPS Intranasal Delivery Device+Empagliflozin 10 MG (Empagliflozin and Intranasal Insulin Placebo)	fugaduamog = jfgkkitmwo koboukuzky (lmcjkzlrxd, fldsyjaudw - djczmphajn) View more
NCT03215069 (Pubmed \| Diabetes Obes Metab)	Phase 2	Diabetes, Gestational	91	Empagliflozin 10 mg/day	xnnxxmjuhb(uldqmwowcz): P-Value = 0.43 View more	Negative	18 Sep 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis